Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Following the sharp policy-driven volatility in early April, U.S. equity markets staged a robust and, to many, unexpected ...

Donald Trump’s threat to impose a 50 per cent tariff on all exports from the EU would deliver a hammer blow to key ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...

Hims & Hers Health, Inc. today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...